Cargando…
End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18
BACKGROUND: In the United Kingdom (UK), in recent influenza seasons, children are offered a quadrivalent live attenuated influenza vaccine (LAIV4), and eligible adults mainly trivalent inactivated vaccine (TIV). AIM: To estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685099/ https://www.ncbi.nlm.nih.gov/pubmed/31387673 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.31.1800488 |
_version_ | 1783442339662921728 |
---|---|
author | Pebody, Richard Djennad, Abdelmajid Ellis, Joanna Andrews, Nick Marques, Diogo F P Cottrell, Simon Reynolds, Arlene J Gunson, Rory Galiano, Monica Hoschler, Katja Lackenby, Angie Robertson, Chris O’Doherty, Mark Sinnathamby, Mary Panagiotopoulos, Nikolaos Yonova, Ivelina Webb, Rebecca Moore, Catherine Donati, Matthew Sartaj, Muhammad Shepherd, Samantha J McMenamin, Jim de Lusignan, Simon Zambon, Maria |
author_facet | Pebody, Richard Djennad, Abdelmajid Ellis, Joanna Andrews, Nick Marques, Diogo F P Cottrell, Simon Reynolds, Arlene J Gunson, Rory Galiano, Monica Hoschler, Katja Lackenby, Angie Robertson, Chris O’Doherty, Mark Sinnathamby, Mary Panagiotopoulos, Nikolaos Yonova, Ivelina Webb, Rebecca Moore, Catherine Donati, Matthew Sartaj, Muhammad Shepherd, Samantha J McMenamin, Jim de Lusignan, Simon Zambon, Maria |
author_sort | Pebody, Richard |
collection | PubMed |
description | BACKGROUND: In the United Kingdom (UK), in recent influenza seasons, children are offered a quadrivalent live attenuated influenza vaccine (LAIV4), and eligible adults mainly trivalent inactivated vaccine (TIV). AIM: To estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the seroprevalence in England of antibodies against influenza viruses cultured in eggs or tissue. METHODS: This observational study employed the test-negative case–control approach to estimate aVE in primary care. The population-based seroprevalence survey used residual age-stratified samples. RESULTS: Influenza viruses A(H3N2) (particularly subgroup 3C.2a2) and B (mainly B/Yamagata/16/88-lineage, similar to the quadrivalent vaccine B-virus component but mismatched to TIV) dominated. All-age aVE was 15% (95% confidence interval (CI): −6.3 to 32) against all influenza; −16.4% (95% CI: −59.3 to 14.9) against A(H3N2); 24.7% (95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 to 82.9) against A(H1N1)pdm09. For 2–17 year olds, LAIV4 aVE was 26.9% (95% CI: −32.6 to 59.7) against all influenza; −75.5% (95% CI: −289.6 to 21) against A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 90.3% (95% CI: 16.4 to 98.9) against A(H1N1)pdm09. For ≥ 18 year olds, TIV aVE against influenza B was 1.9% (95% CI: −63.6 to 41.2). The 2017 seroprevalence of antibody recognising tissue-grown A(H3N2) virus was significantly lower than that recognising egg-grown virus in all groups except 15–24 year olds. CONCLUSIONS: Overall aVE was low driven by no effectiveness against A(H3N2) possibly related to vaccine virus egg-adaption and a new A(H3N2) subgroup emergence. The TIV was not effective against influenza B. LAIV4 against influenza B and A(H1N1)pdm09 was effective. |
format | Online Article Text |
id | pubmed-6685099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | European Centre for Disease Prevention and Control (ECDC) |
record_format | MEDLINE/PubMed |
spelling | pubmed-66850992019-08-26 End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 Pebody, Richard Djennad, Abdelmajid Ellis, Joanna Andrews, Nick Marques, Diogo F P Cottrell, Simon Reynolds, Arlene J Gunson, Rory Galiano, Monica Hoschler, Katja Lackenby, Angie Robertson, Chris O’Doherty, Mark Sinnathamby, Mary Panagiotopoulos, Nikolaos Yonova, Ivelina Webb, Rebecca Moore, Catherine Donati, Matthew Sartaj, Muhammad Shepherd, Samantha J McMenamin, Jim de Lusignan, Simon Zambon, Maria Euro Surveill Research BACKGROUND: In the United Kingdom (UK), in recent influenza seasons, children are offered a quadrivalent live attenuated influenza vaccine (LAIV4), and eligible adults mainly trivalent inactivated vaccine (TIV). AIM: To estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the seroprevalence in England of antibodies against influenza viruses cultured in eggs or tissue. METHODS: This observational study employed the test-negative case–control approach to estimate aVE in primary care. The population-based seroprevalence survey used residual age-stratified samples. RESULTS: Influenza viruses A(H3N2) (particularly subgroup 3C.2a2) and B (mainly B/Yamagata/16/88-lineage, similar to the quadrivalent vaccine B-virus component but mismatched to TIV) dominated. All-age aVE was 15% (95% confidence interval (CI): −6.3 to 32) against all influenza; −16.4% (95% CI: −59.3 to 14.9) against A(H3N2); 24.7% (95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 to 82.9) against A(H1N1)pdm09. For 2–17 year olds, LAIV4 aVE was 26.9% (95% CI: −32.6 to 59.7) against all influenza; −75.5% (95% CI: −289.6 to 21) against A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 90.3% (95% CI: 16.4 to 98.9) against A(H1N1)pdm09. For ≥ 18 year olds, TIV aVE against influenza B was 1.9% (95% CI: −63.6 to 41.2). The 2017 seroprevalence of antibody recognising tissue-grown A(H3N2) virus was significantly lower than that recognising egg-grown virus in all groups except 15–24 year olds. CONCLUSIONS: Overall aVE was low driven by no effectiveness against A(H3N2) possibly related to vaccine virus egg-adaption and a new A(H3N2) subgroup emergence. The TIV was not effective against influenza B. LAIV4 against influenza B and A(H1N1)pdm09 was effective. European Centre for Disease Prevention and Control (ECDC) 2019-08-01 /pmc/articles/PMC6685099/ /pubmed/31387673 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.31.1800488 Text en This article is copyright of the authors or their affiliated institutions, 2019. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
spellingShingle | Research Pebody, Richard Djennad, Abdelmajid Ellis, Joanna Andrews, Nick Marques, Diogo F P Cottrell, Simon Reynolds, Arlene J Gunson, Rory Galiano, Monica Hoschler, Katja Lackenby, Angie Robertson, Chris O’Doherty, Mark Sinnathamby, Mary Panagiotopoulos, Nikolaos Yonova, Ivelina Webb, Rebecca Moore, Catherine Donati, Matthew Sartaj, Muhammad Shepherd, Samantha J McMenamin, Jim de Lusignan, Simon Zambon, Maria End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
title | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
title_full | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
title_fullStr | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
title_full_unstemmed | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
title_short | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
title_sort | end of season influenza vaccine effectiveness in adults and children in the united kingdom in 2017/18 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685099/ https://www.ncbi.nlm.nih.gov/pubmed/31387673 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.31.1800488 |
work_keys_str_mv | AT pebodyrichard endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT djennadabdelmajid endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT ellisjoanna endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT andrewsnick endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT marquesdiogofp endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT cottrellsimon endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT reynoldsarlenej endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT gunsonrory endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT galianomonica endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT hoschlerkatja endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT lackenbyangie endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT robertsonchris endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT odohertymark endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT sinnathambymary endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT panagiotopoulosnikolaos endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT yonovaivelina endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT webbrebecca endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT moorecatherine endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT donatimatthew endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT sartajmuhammad endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT shepherdsamanthaj endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT mcmenaminjim endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT delusignansimon endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT zambonmaria endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 |